Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia

Krzysztof Giannopoulos; Paulina Własiuk; Anna Dmoszyńska; Jacek Roliński; Michael Schmitt

doi:10.5603/FHC.2011.0023

Vol 49, No 1 (2011)

Original paper

Submitted: 2011-12-19

Published online: 2011-04-19

View PDF

Download PDF file

Get Citation

Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia

Krzysztof Giannopoulos, Paulina Własiuk, Anna Dmoszyńska, Jacek Roliński, Michael Schmitt

DOI: 10.5603/FHC.2011.0023

Folia Histochem Cytobiol 2011;49(1):161-167.

Vol 49, No 1 (2011)

ORIGINAL PAPERS

Submitted: 2011-12-19

Published online: 2011-04-19

Abstract

Although the immune status of chronic lymphocytic leukemia (CLL) patients is mostly characterized by immunosuppression, there is an accumulation of in vivo (graft-versus-leukemia effect) and in vitro (spontaneous remissions after infections) data that indicates that CLL might be effectively targeted by T-cell based immunotherapy. Recently, we characterized receptor for hyaluronic acid mediated motility (RHAMM) as a preferential target for immunotherapy of CLL. We also completed a RHAMM-derived peptide vaccination phase I/II clinical trial in CLL. Here, we present a detailed immunological analysis of six CLL patients vaccinated with HLA-A2 restricted RHAMM-derived epitope R3 (ILSLELMKL). Beside effective induction of R3-specific cytotoxic T-cells, peptide vaccination caused profound changes in different T-cell subsets as well as cytokines. We present longitudinal analyses of Th17, CD8⁺CD103⁺, CD8⁺CD137⁺ and IL-17 producing CD8⁺ T cells (CD8⁺IL- -17⁺) as well as important cytokines involved in regulation of immune response such as TGF-β, IL-10, IL-2 and TNF throughout the peptide vaccination period. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 161–167)

Abstract

Although the immune status of chronic lymphocytic leukemia (CLL) patients is mostly characterized by immunosuppression, there is an accumulation of in vivo (graft-versus-leukemia effect) and in vitro (spontaneous remissions after infections) data that indicates that CLL might be effectively targeted by T-cell based immunotherapy. Recently, we characterized receptor for hyaluronic acid mediated motility (RHAMM) as a preferential target for immunotherapy of CLL. We also completed a RHAMM-derived peptide vaccination phase I/II clinical trial in CLL. Here, we present a detailed immunological analysis of six CLL patients vaccinated with HLA-A2 restricted RHAMM-derived epitope R3 (ILSLELMKL). Beside effective induction of R3-specific cytotoxic T-cells, peptide vaccination caused profound changes in different T-cell subsets as well as cytokines. We present longitudinal analyses of Th17, CD8⁺CD103⁺, CD8⁺CD137⁺ and IL-17 producing CD8⁺ T cells (CD8⁺IL- -17⁺) as well as important cytokines involved in regulation of immune response such as TGF-β, IL-10, IL-2 and TNF throughout the peptide vaccination period. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 161–167)

Full Text:
View PDF Download PDF file

Get Citation

Keywords

B-cell chronic lymphocytic leukemia (CLL); receptor for hyaluronic acid mediated motility (RHAMM); peptide immunotherapy

About this article

Title

Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 1 (2011)

Article type

Original paper

Pages

161-167

Published online

2011-04-19

Page views

1985

Article views/downloads

2216

DOI

10.5603/FHC.2011.0023

Bibliographic record

Folia Histochem Cytobiol 2011;49(1):161-167.

Keywords

B-cell chronic lymphocytic leukemia (CLL)
receptor for hyaluronic acid mediated motility (RHAMM)
peptide immunotherapy

Authors

Krzysztof Giannopoulos
Paulina Własiuk
Anna Dmoszyńska
Jacek Roliński
Michael Schmitt